Sigilon Therapeutics SGTX
$ 22.47
0.0%
Quarterly report 2023-Q2
added 08-07-2023
Sigilon Therapeutics Balance Sheet 2011-2024 | SGTX
Annual Balance Sheet Sigilon Therapeutics
2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-25.6 M | -83.9 M | -177 M | -51 M | -59.1 M | - | - | - | - | - | - | - |
Long Term Debt |
12 M | 18.4 M | 19.8 M | 14.9 M | 4.29 M | - | - | - | - | - | - | - |
Long Term Debt Current |
4.48 M | 4.84 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 31.9 M | 128 M | 74.6 M | - | - | - | - | - | - | - |
Total Current Liabilities |
31 M | 34.9 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
48.1 M | 67.2 M | 78.9 M | 168 M | 104 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | 31.8 M | 29.1 M | 24.7 M | - | - | - | - | - | - | - |
Retained Earnings |
-257 M | -213 M | -136 M | -81.3 M | -37.4 M | - | - | - | - | - | - | - |
Total Assets |
87.3 M | 144 M | 225 M | 90.4 M | 67.7 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
42.1 M | 107 M | 203 M | - | - | - | - | - | - | - | - | - |
Book Value |
39.1 M | 77.2 M | 146 M | -77.8 M | -36.1 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
39.1 M | 77.2 M | 146 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Sigilon Therapeutics
2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
2.86 M | 10.4 M | 12 M | 13.6 M | - | 16.8 M | 18.4 M | 20 M | 20 M | 20 M | 19.8 M | 20 M | 20 M | 20 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
28.1 M | 43.3 M | 48.1 M | 50.2 M | - | 61.6 M | 67.2 M | 70.5 M | 75.1 M | 74.4 M | 78.9 M | 78.9 M | 78.9 M | 78.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-272 M | -264 M | -257 M | -250 M | - | -227 M | -213 M | -195 M | -175 M | -155 M | -136 M | -136 M | -136 M | -136 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
55.6 M | 76.6 M | 87.3 M | 94.6 M | - | 126 M | 144 M | 164 M | 186 M | 203 M | 225 M | 225 M | 225 M | 225 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
19.6 M | 41.3 M | 42.1 M | 32.9 M | 35.9 M | 161 M | 107 M | 142 M | 162 M | 179 M | 202 M | 202 M | 202 M | 202 M | 76.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
27.4 M | 33.3 M | 39.1 M | 44.4 M | - | 64.6 M | 77.2 M | 93.3 M | 111 M | 129 M | 146 M | 146 M | 146 M | 146 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
27.4 M | 33.3 M | 39.1 M | 44.4 M | 51.8 M | 64.6 M | 77.2 M | 93.3 M | 111 M | 129 M | 146 M | 146 M | 146 M | 146 M | -77.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency